Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Quarterly Statistics, Q1 2013

This article was originally published in Start Up

Executive Summary

Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.

You may also be interested in...



AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology

The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.

Resolve Scores The Option Of An Exit With Takeda Tie-Up

Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.

RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year

Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel